Company news
31.08.10
Lab21 launches new commercial companion diagnostic service for HIV tropism in UK →
26.08.10
Lab21 licences pharmacogenetic IP for CES-1 from MUSC →
01.06.10
Lab21 achieves first product registration in China →
24.05.10
Lab21 and Virco partner to offer UK-based HIV-1 genotyping services →
18.12.09
Lab21 acquires US nanotechnology company and establishes Lab21 Inc. in South Carolina →
26.11.09
Lab21 acquires personalised medicine diagnostic services business →
Facilities
Facilities
Lab21 operates from extensive, state of the art laboratories, which include a Category 3 containment facility at its Cambridge site. Investment in future-proofed LIMS technology from an established supplier helps ensure that external regulatory requirements for public health, pharmaceutical and environmental industries are met. Furthermore, Lab21 is committed to an active, ongoing quality programme that ensures the highest standards of management, testing and service delivery.
- Procedures are consistent with the US Clinical Laboratory Improvement Amendments (CLIA) program, designed to ensure quality laboratory testing
- All work is conducted following the principles of Good Laboratory Practice (GLP) and where applicable Good Clinical Practice (GCP)
- The company is working towards ISO quality system requirements specific to the medical industry
- STARLIMS system ensures complete traceability and regulatory compliance
- The company is working towards manufacturing the reagents for environmental systems and analysis in accordance with ISO 9001:2000 standards - Lab21 Environmental
Technical facilities
Science Park, Cambridge
- 10,000 sq ft
- New, state of the art IT & Telecoms infrastructure
- Custom made, modern laboratories
- Dedicated Category 3 containment suite
- Dedicated Category 2 cell culture suite
- Dedicated PCR suite
- StarLIMS Laboratory Information Management System
Working towards GLP and ISO certification in 2006
- Capabilities/Technical Expertise (Healthcare)
- Molecular Biology/Real time PCR, Virology screening
- Pre-Clinical Trials contract research
- Pharmacogenetics
- Cancer diagnostics
- Human/pathogen genotyping
